Hikma Pharmaceuticals PLC
HKMPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3,127 | $2,875 | $2,517 | $2,553 |
| % Growth | 8.8% | 14.2% | -1.4% | – |
| Cost of Goods Sold | $1,712 | $1,468 | $1,252 | $1,252 |
| Gross Profit | $1,415 | $1,407 | $1,265 | $1,301 |
| % Margin | 45.3% | 48.9% | 50.3% | 51% |
| R&D Expenses | $141 | $149 | $144 | $143 |
| G&A Expenses | $568 | $638 | $509 | $488 |
| SG&A Expenses | $568 | $632 | $509 | $488 |
| Sales & Mktg Exp. | $0 | -$6 | $0 | $0 |
| Other Operating Expenses | $94 | $259 | $323 | $88 |
| Operating Expenses | $803 | $1,040 | $976 | $719 |
| Operating Income | $612 | $367 | $282 | $582 |
| % Margin | 19.6% | 12.8% | 11.2% | 22.8% |
| Other Income/Exp. Net | -$157 | -$86 | -$49 | -$38 |
| Pre-Tax Income | $455 | $281 | $233 | $544 |
| Tax Expense | $93 | $89 | $42 | $124 |
| Net Income | $359 | $190 | $188 | $421 |
| % Margin | 11.5% | 6.6% | 7.5% | 16.5% |
| EPS | 1.62 | 0.85 | 0.84 | 1.82 |
| % Growth | 90.6% | 1.2% | -53.8% | – |
| EPS Diluted | 1.61 | 0.85 | 0.84 | 1.81 |
| Weighted Avg Shares Out | 221 | 224 | 224 | 231 |
| Weighted Avg Shares Out Dil | 223 | 222 | 225 | 233 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8 | $7 | $3 | $1 |
| Interest Expense | $75 | $89 | $69 | $55 |
| Depreciation & Amortization | $179 | $172 | $193 | $144 |
| EBITDA | $787 | $791 | $691 | $705 |
| % Margin | 25.2% | 27.5% | 27.5% | 27.6% |